SCHEMBL150083

SCHEMBL150083

NC(=O)c1ccc(Br)c2c3c([nH]c12)CCCC3

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.58
ALOX15 P16050 2/20 0.58
MAPK1 P28482 2/20 0.58
CASP1 P29466 1/20 0.58
CASP7 P55210 1/20 0.58
ALDH1A1 P00352 2/20 0.56
MAPT P10636 2/20 0.56
MEN1 O00255 1/20 0.56
IKBKB O14920 1/20 0.56
USP2 O75604 1/20 0.56
TP53 P04637 1/20 0.56
MAPK10 P53779 1/20 0.56
KMT2A Q03164 1/20 0.56
BTK Q06187 11/20 0.49
JAK2 O60674 1/20 0.46
GFER P55789 1/20 0.43
ERN1 O75460 1/20 0.35
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL148202 0.87 GFER (0.57) HSD17B10ALOX15MAPK1CASP1CASP7
SCHEMBL21509052 0.84 ALOX15 (0.59) HSD17B10ALOX15MAPK1CASP1CASP7
SCHEMBL9984001 0.83 NISCH (0.48) HSD17B10ALOX15MAPK1CASP1CASP7
SCHEMBL30159980 0.81 HSD17B10 (0.41) HSD17B10ALOX15MAPK1CASP1CASP7
SCHEMBL30159876 0.81 ALOX15 (0.41) HSD17B10ALOX15MAPK1CASP1CASP7
SCHEMBL12071375 0.79 ALOX15 (0.40) HSD17B10ALOX15MAPK1CASP1CASP7
SCHEMBL19279340 0.79 BTK (0.55) HSD17B10ALOX15MAPK1CASP1CASP7
SCHEMBL19715405 0.79 BTK (0.55) BTKJAK2
SCHEMBL19715408 0.79 BTK (0.54) BTKJAK2
SCHEMBL150132 0.78 BTK (0.46) BTKJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11053197-B2 Carbazole derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2021-07-06 US disclosed
US-11053197-B2 Carbazole derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2021-07-06 US disclosed
US-20200255377-A1 CARBAZOLE DERIVATIVES Organization Name: BRISTOL-MYERS SQUIBB COMPANY (US) 2020-08-13 US disclosed
US-20200255377-A1 CARBAZOLE DERIVATIVES Organization Name: BRISTOL-MYERS SQUIBB COMPANY (US) 2020-08-13 US disclosed
US-10676434-B2 Carbazole derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2020-06-09 US disclosed
US-10676434-B2 Carbazole derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2020-06-09 US disclosed
EP-3209651-B9 CARBAZOLE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2020-05-20 EP disclosed
EP-3209651-B9 CARBAZOLE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2020-05-20 EP disclosed
CN-107074804-B Carbazole derivatives 百时美施贵宝公司 2020-02-18 CN disclosed
EP-3209651-B1 CARBAZOLE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2019-10-23 EP disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
EP-2391602-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-12-07 EP disclosed
WO-2010080481-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed
WO-2010080481-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 HSD17B10 3992/4885ALOX15 4154/4885MAPK1 239/4885
US-10676434-B2 Carbazole derivatives BTK, SYK, JAK2 HSD17B10 4222/4885ALOX15 4176/4885MAPK1 340/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 HSD17B10 3992/4885ALOX15 4154/4885MAPK1 239/4885
US-11053197-B2 Carbazole derivatives BTK, SYK, JAK2 HSD17B10 4222/4885ALOX15 4176/4885MAPK1 340/4885
US-20200255377-A1 CARBAZOLE DERIVATIVES BTK, SYK, JAK2 HSD17B10 4222/4885ALOX15 4176/4885MAPK1 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.